AnaptysBio, Inc. (ANAB) Exceeds Expectations for Q3 Earnings and Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy ANAB?
Source: NASDAQ.COM
Earnings Performance: AnaptysBio, Inc. reported quarterly earnings of $0.52 per share, significantly beating the Zacks Consensus Estimate of a loss of $1.06 per share, marking a 149.06% earnings surprise.
Revenue Growth: The company generated revenues of $76.32 million for the quarter, surpassing expectations by 145.36% and showing substantial growth from $30.02 million a year ago.
Stock Performance: AnaptysBio shares have increased by approximately 172.2% since the start of the year, outperforming the S&P 500's 16.5% gain, but future performance will depend on management's commentary and earnings outlook.
Industry Outlook: The Medical - Biomedical and Genetics industry ranks in the top 39% of Zacks industries, indicating a favorable environment, while Ovid Therapeutics is expected to report a quarterly loss with a revenue increase of 100% year-over-year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANAB
Wall Street analysts forecast ANAB stock price to rise
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 57.400
Low
50.00
Averages
74.13
High
140.00
Current: 57.400
Low
50.00
Averages
74.13
High
140.00
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AnaptysBio Approves Spin-Off of First Tracks Biotherapeutics
- Spin-Off Announcement: AnaptysBio has approved the spin-off of First Tracks Biotherapeutics, with the new entity expected to begin trading on Nasdaq under the ticker “TRAX” on April 20, 2026, potentially unlocking new market opportunities.
- Financial Management: Post-spin-off, AnaptysBio will manage financial collaborations for Jemperli with GSK and imsidolimab with Vanda, ensuring the continued development and competitiveness of its core product lines.
- Financial Position: The new company will launch operations with approximately $140-$145 million in net cash and investments while maintaining limited full-time employees and minimal operating expenses to achieve efficient financial management.
- Stock Repurchase Plan: AnaptysBio has also announced a $100 million stock repurchase plan aimed at buying back outstanding common stock, which could enhance shareholder value and boost market confidence.
See More
AnaptysBio Announces $100 Million Buyback and Business Update
- Buyback Plan: AnaptysBio's board has authorized a stock repurchase plan of up to $100 million, aimed at enhancing shareholder value and boosting market confidence.
- Business Restructuring: The company plans to spin off its biopharma operations into First Tracks Biotherapeutics by April 20, focusing on financial collaborations with GSK and Vanda, which is expected to free up resources for core operations.
- Financial Position: Post-spin-off, AnaptysBio anticipates having between $140 million and $145 million in net cash and investments, ensuring financial flexibility for future operations.
- Operational Efficiency: The company aims to keep annual operating expenses below $10 million while achieving an EBIT margin exceeding 95%, supporting sustainable growth and profitability.
See More
Anaptys Announces Spin-Off of Biopharma Operations
- Biopharma Spin-Off: Anaptys plans to spin off its biopharma operations into First Tracks Biotherapeutics on April 20, 2026, aiming to enhance overall financial performance by focusing on protecting and returning shareholder value.
- Stock Repurchase Plan: The company announced a stock repurchase plan of up to $100 million, expected to repurchase common stock through market transactions, thereby boosting shareholder confidence and enhancing shareholder value.
- Board Expansion: Anaptys appointed Susannah Gray, former CFO of Royalty Pharma, to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical sector, which will provide valuable financial and capital markets expertise to the company.
- Operational Model Optimization: Post-spin-off, Anaptys will adopt a virtual operating model with anticipated annual operating expenses of less than $10 million and an EBIT margin exceeding 95%, ensuring efficient financial management and resource allocation.
See More
First Tracks Biotherapeutics Secures $145 Million in Private Placement Financing
- Financing Size: First Tracks Biotherapeutics has successfully secured $145 million in private placement financing through an agreement with third-party investors, including $80 million in initial proceeds, which is expected to provide ample cash flow to support operations for the next two years.
- Equity Sale Details: In this transaction, First Tracks Biotherapeutics is selling 5,791,478 shares of common stock at a price of $13.81 per share, resulting in $80 million in gross proceeds, which will be utilized for general corporate purposes, including clinical development.
- Investor Participation: The financing attracted participation from several new and existing investors, including 683 Capital Partners and Adage Capital, demonstrating strong market confidence in First Tracks Biotherapeutics' future growth while providing robust funding support for its product development.
- Spin-off Outlook: First Tracks Biotherapeutics plans to complete its spin-off from AnaptysBio on April 20, 2026, and the successful financing will lay the groundwork for its independent operations, providing essential funding for the development of its clinical candidate ANB033.
See More
First Tracks Biotherapeutics Spin-Off Date Set
- Spin-Off Date Confirmed: AnaptysBio's Board has approved the spin-off of First Tracks Biotherapeutics, expected to begin trading on April 20, 2026, marking a significant strategic restructuring aimed at unlocking potential value in autoimmune disease therapies.
- Shareholder Distribution: AnaptysBio shareholders will receive one share of First Tracks Bio common stock for each share of AnaptysBio held, with a record date of April 6, 2026, enhancing shareholder returns and boosting market confidence in the new entity.
- Initial Capital Position: First Tracks Bio will launch with $180 million in cash, including $100 million from Anaptys and $80 million from oversubscribed private placement financing, ensuring sufficient funding for its clinical-stage antibody therapeutic development over the next two years.
- Leadership Team Formation: The executive team for First Tracks Bio will include Anaptys' Daniel Faga as CEO, with the anticipated appointment of Ajim Tamboli, a life sciences veteran with over 25 years of experience, as CFO, establishing a strong leadership foundation for success in the biotechnology sector.
See More
ANAPTYSBIO INC - AJIM TAMBOLI LIKELY TO BE NAMED CFO OF FIRST TRACKS BIO
- New Appointment: A new Chief Financial Officer (CFO) is expected to be appointed for First Tracks Bio.
- Leadership Change: The appointment of the CFO is part of a broader leadership transition within the company.
See More
AnaptysBio Approves Spin-Off of First Tracks Biotherapeutics
- Spin-Off Announcement: AnaptysBio has approved the spin-off of First Tracks Biotherapeutics, with the new entity expected to begin trading on Nasdaq under the ticker “TRAX” on April 20, 2026, potentially unlocking new market opportunities.
- Financial Management: Post-spin-off, AnaptysBio will manage financial collaborations for Jemperli with GSK and imsidolimab with Vanda, ensuring the continued development and competitiveness of its core product lines.
- Financial Position: The new company will launch operations with approximately $140-$145 million in net cash and investments while maintaining limited full-time employees and minimal operating expenses to achieve efficient financial management.
- Stock Repurchase Plan: AnaptysBio has also announced a $100 million stock repurchase plan aimed at buying back outstanding common stock, which could enhance shareholder value and boost market confidence.
See More
AnaptysBio Announces $100 Million Buyback and Business Update
- Buyback Plan: AnaptysBio's board has authorized a stock repurchase plan of up to $100 million, aimed at enhancing shareholder value and boosting market confidence.
- Business Restructuring: The company plans to spin off its biopharma operations into First Tracks Biotherapeutics by April 20, focusing on financial collaborations with GSK and Vanda, which is expected to free up resources for core operations.
- Financial Position: Post-spin-off, AnaptysBio anticipates having between $140 million and $145 million in net cash and investments, ensuring financial flexibility for future operations.
- Operational Efficiency: The company aims to keep annual operating expenses below $10 million while achieving an EBIT margin exceeding 95%, supporting sustainable growth and profitability.
See More
Anaptys Announces Spin-Off of Biopharma Operations
- Biopharma Spin-Off: Anaptys plans to spin off its biopharma operations into First Tracks Biotherapeutics on April 20, 2026, aiming to enhance overall financial performance by focusing on protecting and returning shareholder value.
- Stock Repurchase Plan: The company announced a stock repurchase plan of up to $100 million, expected to repurchase common stock through market transactions, thereby boosting shareholder confidence and enhancing shareholder value.
- Board Expansion: Anaptys appointed Susannah Gray, former CFO of Royalty Pharma, to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical sector, which will provide valuable financial and capital markets expertise to the company.
- Operational Model Optimization: Post-spin-off, Anaptys will adopt a virtual operating model with anticipated annual operating expenses of less than $10 million and an EBIT margin exceeding 95%, ensuring efficient financial management and resource allocation.
See More
First Tracks Biotherapeutics Secures $145 Million in Private Placement Financing
- Financing Size: First Tracks Biotherapeutics has successfully secured $145 million in private placement financing through an agreement with third-party investors, including $80 million in initial proceeds, which is expected to provide ample cash flow to support operations for the next two years.
- Equity Sale Details: In this transaction, First Tracks Biotherapeutics is selling 5,791,478 shares of common stock at a price of $13.81 per share, resulting in $80 million in gross proceeds, which will be utilized for general corporate purposes, including clinical development.
- Investor Participation: The financing attracted participation from several new and existing investors, including 683 Capital Partners and Adage Capital, demonstrating strong market confidence in First Tracks Biotherapeutics' future growth while providing robust funding support for its product development.
- Spin-off Outlook: First Tracks Biotherapeutics plans to complete its spin-off from AnaptysBio on April 20, 2026, and the successful financing will lay the groundwork for its independent operations, providing essential funding for the development of its clinical candidate ANB033.
See More
First Tracks Biotherapeutics Spin-Off Date Set
- Spin-Off Date Confirmed: AnaptysBio's Board has approved the spin-off of First Tracks Biotherapeutics, expected to begin trading on April 20, 2026, marking a significant strategic restructuring aimed at unlocking potential value in autoimmune disease therapies.
- Shareholder Distribution: AnaptysBio shareholders will receive one share of First Tracks Bio common stock for each share of AnaptysBio held, with a record date of April 6, 2026, enhancing shareholder returns and boosting market confidence in the new entity.
- Initial Capital Position: First Tracks Bio will launch with $180 million in cash, including $100 million from Anaptys and $80 million from oversubscribed private placement financing, ensuring sufficient funding for its clinical-stage antibody therapeutic development over the next two years.
- Leadership Team Formation: The executive team for First Tracks Bio will include Anaptys' Daniel Faga as CEO, with the anticipated appointment of Ajim Tamboli, a life sciences veteran with over 25 years of experience, as CFO, establishing a strong leadership foundation for success in the biotechnology sector.
See More
ANAPTYSBIO INC - AJIM TAMBOLI LIKELY TO BE NAMED CFO OF FIRST TRACKS BIO
- New Appointment: A new Chief Financial Officer (CFO) is expected to be appointed for First Tracks Bio.
- Leadership Change: The appointment of the CFO is part of a broader leadership transition within the company.
See More
